- $9.58bn
- $9.41bn
- $638.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 105.08 | ||
| PEG Ratio (f) | 23 | ||
| EPS Growth (f) | 4.79% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.86 | ||
| Price to Tang. Book | 16.41 | ||
| Price to Free Cashflow | 127.83 | ||
| Price to Sales | 14.99 | ||
| EV to EBITDA | 85.52 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.57% | ||
| Return on Equity | 2.14% | ||
| Operating Margin | 6.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 270.25 | 366.26 | 670.53 | 801.54 | 638.76 | 635.62 | 736.53 | 26.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +85.66 | +105.19 | +55.37 | +43.78 | -54.75 | -8.74 | +41.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Directors
- Karen Dawes CHM (69)
- Anthony Hunt PRE (57)
- Jon Snodgres CFO (55)
- James Bylund COO (58)
- Christine Gebski SVP (53)
- Ralf Kuriyel SVP (62)
- Nicolas Barthelemy IND (55)
- Carrie Manner IND (46)
- Rohin Mhatre IND (56)
- Glenn Muir IND (62)
- Thomas Ryan IND (79)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 29th, 1981
- Public Since
- April 29th, 1986
- No. of Shareholders
- 259
- No. of Employees
- 1,783
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 55,838,548
- Address
- BUILDING 1, SUITE 100, 41 SEYON STREET, WALTHAM, 02453
- Web
- https://www.repligen.com/
- Phone
- +1 7814499560
- Auditors
- Ernst & Young LLP
Upcoming Events for RGEN
Repligen Corp Annual Shareholders Meeting
Repligen Corp Annual Shareholders Meeting
Q2 2024 Repligen Corp Earnings Release
Similar to RGEN
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Repligen share price?
As of Today at 19:18 UTC, shares in Repligen are trading at $171.53. This share price information is delayed by 15 minutes.
How has the Repligen share price performed this year?
Shares in Repligen last closed at $171.53 and the price had moved by -4.87% over the past 365 days. In terms of relative price strength the Repligen share price has underperformed the S&P500 Index by -23.17% over the past year.
What are the analyst and broker recommendations for Repligen?
The overall consensus recommendation for Repligen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Repligen dividend yield?
Repligen does not currently pay a dividend.
Does Repligen pay a dividend?
Repligen does not currently pay a dividend.
When does Repligen next pay dividends?
Repligen does not currently pay a dividend.
How do I buy Repligen shares?
To buy shares in Repligen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Repligen?
As of the previous close price of $171.53, shares in Repligen had a market capitalisation of $9.58bn.
Where are Repligen shares listed?
Here are the trading details for Repligen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RGEN
What kind of share is Repligen?
Based on an overall assessment of its quality, value and momentum Repligen is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Repligen share price forecast for 2024?
The analyst consensus target price for shares in Repligen is $204.62. That is 19.29% above the last closing price of $171.53.
Analysts covering Repligen currently have a consensus Earnings Per Share (EPS) forecast of $1.46 for the next financial year.
What is the trend in the Repligen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Repligen. Over the past six months, its share price has underperformed the S&P500 Index by -4.13%.
As of the last closing price of $171.53, shares in Repligen were trading +1.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Repligen PE Ratio?
The Repligen PE ratio based on its reported earnings over the past 12 months is 105.08. The shares last closed at $171.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Repligen?
Repligen's management team is headed by:
- Karen Dawes - CHM
- Anthony Hunt - PRE
- Jon Snodgres - CFO
- James Bylund - COO
- Christine Gebski - SVP
- Ralf Kuriyel - SVP
- Nicolas Barthelemy - IND
- Carrie Manner - IND
- Rohin Mhatre - IND
- Glenn Muir - IND
- Thomas Ryan - IND